Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, ...
During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in ...
A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma ...
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
10-Year Data Support Pembrolizumab as Standard for Advanced Melanoma ...
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback